Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
Status:
COMPLETED
Trial end date:
2024-10-16
Target enrollment:
Participant gender:
Summary
The study is a placebo-controlled, double-blind, randomized, phase 3 study in participants with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk factors to evaluate the efficacy, safety and tolerability of obicetrapib 10mg and ezetimibe 10mg fixed dose combination as an adjunct to diet and maximally tolerated lipid-lowering therapy.
Phase:
PHASE3
Details
Lead Sponsor:
NewAmsterdam Pharma
Treatments:
Cholesterol Ester Transfer Proteins Combined Modality Therapy Ezetimibe